Fluidigm Corporation (Fluidigm) develops, manufactures and markets microfluidic systems such as single-cell genomics, applied genotyping and sample preparation for targeted resequencing, in the life science and agricultural biotechnology, or Ag-Bio, industries. The Company�s microfluidic systems consist of instruments and consumables, including chips and reagents. It markets three microfluidic systems, including eight different commercial chips to pharmaceutical and biotechnology companies, academic institutions, diagnostic laboratories companies. The Company sells three microfluidic systems, BioMark, EP1 and Access Array. All of its systems include chip controllers that control the activation of valves, loading of reagents, and recovery or wash steps within the chips. Each chip controller comes with software to control chip and instrument operations for particular applications.